Bliss GVS Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Bliss GVS Pharma Ltd. on BSE

Search Inside the pdf :

Bliss GVS Pharma Ltd.

21 Feb 2025

117.62

4.63%

SAST

BLISS GVS PHARMA LTD. - 506197 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Narsimha Shibroor Kamath & PACs

pdf

Bliss GVS Pharma Ltd.

21 Feb 2025

117.62

4.63%

SAST

BLISS GVS PHARMA LTD. - 506197 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Narsimha Shiboor Kamath & PACs

pdf

Bliss GVS Pharma Ltd.

30 Jan 2025

117.62

4.63%

Corp. Note

BLISS GVS PHARMA LTD. - 506197 - Integrated Filing (Financial)

BSE India

Please find attached Intergrated Filing (Financial) for the quarter and nine months ended December 31, 2024

pdf

Bliss GVS Pharma Ltd.

30 Jan 2025

117.62

4.63%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached herewith the copies of the Newspaper publication regarding the Unaudited Standalone and Consolidated Financial Results of the Company of the Company for the quarter and nine months ended December 31, 2024

pdf

Bliss GVS Pharma Ltd.

29 Jan 2025

117.62

4.63%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, …

BSE India

Please find attached herewith a certificate received from MUFG Intime India Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities Exchange Board of India (Despositories and Participants) Regulations, 2018 for the quarter ended December 31, 2024.

pdf

Bliss GVS Pharma Ltd.

28 Jan 2025

117.62

4.63%

Result

BLISS GVS PHARMA LTD. - 506197 - Unaudited Standalone And Consolidated Financial Results Of The Company …

BSE India

Please find attached the outcome of Board Meeting held on Tuesday, January 28, 2025.

pdf

	Dec 2024	Sep 2024	Dec 2023	Change QoQ%	Change YoY%
Total Revenue Qtr	225.68	222.72	206.14	1.3%	9.5%
Operating Profit Qtr	29.79	41.48	43.69	-28.2%	-31.8%
Net Profit Qtr	23.80	24.26	27.61	-1.9%	-13.8%
Earning Per Share Adjusted latest Qtr	2.26	2.30	2.62	-1.7%	-13.7%

* Consolidated data

Detailed Results

Bliss GVS Pharma Ltd.

28 Jan 2025

117.62

4.63%

Board Meeting

BLISS GVS PHARMA LTD. - 506197 - Board Meeting Outcome for Outcome Of Board Meeting

BSE India

Please find the attached Outcome of Board Meeting held on Tuesday, January 28, 2025.

pdf

Bliss GVS Pharma Ltd.

21 Jan 2025

117.62

4.63%

Board Meeting

BLISS GVS PHARMA LTD. - 506197 - Board Meeting Intimation for Unaudited Standalone And Consolidated Financial …

BSE India

BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 ,inter alia, to consider and approve The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024; and The proposal for issuance of Sweat Equity Shares pursuant to applicable provisions of the Companies Act, 2013, the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and other applicable laws and regulations to Key Managerial Personnel and/or Senior Management Personnel and/or Employee(s) of the Company including determination of the issue price if any, subject to such regulatory and statutory approvals as may be required including approval of the shareholders of the Company.

pdf

Bliss GVS Pharma Ltd.

16 Jan 2025

117.62

4.63%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Enclosed herewith please find attached the Intimation regarding the completion of service of Mr. Dinesh Shetty, General Manager of the Company in accordance with the Company''s superannuation policy.

pdf

Bliss GVS Pharma Ltd.

07 Jan 2025

117.62

4.63%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

We like to inform you that, the ESOP Allotment Committee of the Company at its meeting held on January 07, 2025, has approved the allotment of 4,000 equity shares of the face value of Re. 1/-each to the eligible employee who have exercised their stock options under Bliss GVS Pharma Limited-Employee Stock Option Plan ("Bliss GVS ESOP-2019").

pdf

No results found

Is Bliss GVS Pharma Ltd. worth buying?

164 Votes:

Buy 82.32%

Sell 7.93%

Hold 9.76%